The 30th Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP) took place on 25–26 September 2025 at the Oviedo Exhibition and Congress Centre, marking a highly successful edition hosted jointly by ISCP and ASTURCOR.

The meeting gathered leading clinicians, clinical pharmacologists, researchers, and trainees from across the world to discuss advances in cardiovascular pharmacotherapy, emerging therapeutics, and real-world clinical challenges. With a strong focus on multidisciplinary collaboration, the programme combined high-level science, clinical sessions, and interactive workshops.

The ISCP 2025 Annual Scientific Meeting achieved strong international participation, robust scientific exchange, and exceptional quality in both presentations and discussions. The diversity of sessions—from cutting-edge pharmacotherapy updates to multidisciplinary approaches and hands-on workshops—reinforced ISCP’s mission to advance knowledge and improve cardiovascular patient care worldwide.

The success of the congress reflects the collaboration between ISCP, ASTURCOR, the scientific committee, speakers, and delegates from around the globe.

Organisation & Logistics

Co-organisers

• ISCP – International Society of Cardiovascular Pharmacotherapy

• ASTURCOR – Asociación Asturiana de Cardiología

Local Scientific & Organising Committee

• Prof. Pablo Avanzas

• Dr. Jesús María de la Hera

• Prof. Antoni Martínez-Rubio

• Prof. Gheorghe-Andrei Dan

• Prof. Juan Carlos Kaski

• Prof. Koji Hasegawa

• Prof. Isaac Pascual

• Dr. Rebeca Lorca

• Dr. Rut Álvarez

• Dr. Marcel Almendárez

• Dr. Iria Silva

• Dr. José Miguel Álvarez Cabo

• Dr. Daniel Moro

Technical Secretariat

CADE Comunicación - Oviedo, Spain

Venue

The meeting was held in the emblematic Oviedo Exhibition and Congress Centre built in the area of Buenavista by the architect Santiago Calatrava, Prince of Asturias Prize for the Arts 1999.

The Conference Centre is a spectacular 15,640 square metre white building made of concrete, steel and glass in the shape of a shell, with the characteristic giant ribs that are typical of this architect and that can be accessed via a glazed surface. The complex also includes several offices for the Government of the Principality of Asturias, a hotel, a big shopping centre and a parking for 1800 cars.

The Congress Centre and its Main Hall is further enhanced by the whiteness of the whole facility, a typical feature of buildings designed by Santiago Calatrava. This building has become a icon in Oviedo due to its impressive and avant-garde striking architecture.

Participation and Demographics

This year’s congress registered 260 total enrolments.

Participants by Professional Profile

• 100 physicians

• 28 residents

• 7 pharmacists / pharmacology specialists

• 90 students

• Others: industry delegates, researchers, and allied health professionals

International Representation

Delegates attended from 15 countries, reaffirming ISCP’s global reach:

Spain, Argentina, Portugal, Peru, UK, Germany, Italy, Japan, Poland, Sweden, Greece, Brazil, Thailand, Romania, Switzerland

Young Investigator / Trainee Support

• 27 scholarships awarded to residents

• No travel grants were issued this year

Scientific Contributions

Abstracts

• 39 abstracts submitted

• 38 accepted, 1 withdrawn by author

• 34 posters

• 4 oral communications

These included clinical studies, pharmacotherapy reviews, real-world evidence projects, case series, and mechanistic analyses in cardiovascular medicine.

Access the ISCP 2025 Best Posters

Awards & Recognitions

The scientific committee recognised outstanding contributions among accepted abstracts:

Best Abstracts

• Daniel Iglesias (Spain, HUCA)

Delay Between Peak Electrophysiological Effect and Diagnostic Response in the Ajmaline Challenge for Brugada Syndrome

• Theodora Cristina Cruz de Assis (Brazil)

Efficacy and Safety of Ongericimab Use in Hypercholesterolemia or Mixed Dyslipidemia: Systematic Review & Meta-analysis

• Cristina Helguera (Spain, HUCA)

Influence of Antiplatelet Therapy Compliance and Clinical Risk Factors on Stent Thrombosis Outcomes.

• Jordi Cahis (Spain, Parc Taulí)

Effects of Pharmacological Treatment on Prevention of MACE at One Year in Takotsubo Syndrome.

Programme Structure

The scientific programme consisted of 11 scientific sessions, 2 keynote lectures, and 1 hands-on workshop. The sessions encompassed metabolic disease, lipid management, hypertension, heart failure, obesity, cardiomyopathies, arrhythmias, CKD, cardio-oncology, interventional cardiology, and adherence/persistence challenges.

Opening Ceremony

Pablo Avanzas (Spain)

Jesús María de la Hera (Spain)

Scientific Highlights

Below is a synthesized overview of the academic content delivered over the two days.

Keynote Lectures

Prof Henry H. Neufeld Keynote Lecture

“New cardiovascular drugs on the horizon”

Speaker: Prof. Juan Tamargo (Spain)

A comprehensive overview of emerging pharmacological agents targeting heart failure, arrhythmias, hypertension, and metabolic disease, including updates on novel pathways and first-in-class therapies.

Keynote Lecture 2

“Wine consumption and Mediterranean diet: The key for longevity in Spain?”

Speaker: Prof. Miguel Ángel Martínez (Spain)

An evidence-based review of diet patterns, polyphenols, and cardiovascular outcomes, with new data from Spanish cohort studies.

Scientific Sessions

Session 1 – Diabetes Mellitus in 2025

Focus: metabolic control, SGLT2i/GLP-1 RA expansion, technology-assisted diabetes care

Speakers included: T. González, K. Filipiak, E. Delgado

Session 2 – Secondary Prevention (Joint Session with Primastcar)

New lipid therapies, statin alternatives, FH management, national survey data

Speakers included: S. Hevia, J. Rondán, R. Alonso, A. Lorenzatti, J. Ares, J. Casares

Workshop – Playing With Drug Interactions

Interactive case-based session led by C. Fernández and I. Maray.

Session 3 – Specific Peculiarities of Heart Failure

Advanced HF pharmacotherapy in special populations

Speakers: A. Martínez-Rubio, G-A. Dan, K. Hasegawa

Session 4 – When Medical Treatment Is Not Enough

Interventional strategies: edge-to-edge repair, TAVR, CRT, new stents

Speakers: I. Pascual, R. del Valle, F. Fastenrath, M. Almendárez

Session 6 – New Perspectives in Hypertension (Joint with EAPE)

Updated therapeutic approaches, novel drug classes, CV risk reduction

Speakers: D. Cokkinos, J.M. Fernández, C. Amodeo, T. Kahan, G-A. Dan

Session 7 – Obesity (Joint with the Spanish Society of Cardiology)

Lifestyle, pharmacotherapy, and the evolving role of cardiologists

Speakers: T. González, L.R. Padial, A. Martínez-Rubio

Session 8 – Cardio-Oncology

Prevention of HF from cancer therapy and antithrombotic considerations

Speakers: R. Lorca, C. Iglesias

Session 9 – Cardiomyopathies: New Pharmacological Therapies

Updates in HCM, amyloidosis, Fabry-Anderson disease, microcirculation

Speakers: R. Lorca, J.C. Kaski, M. Basurte, A. Fidalgo

Session 10 – Long-Term Pharmacotherapy & Patient Interaction

Adherence, socioeconomic barriers, strategies to improve persistence

Speakers: A. Martínez-Rubio, I. Maray

Session 11 – Atrial Fibrillation

XI inhibitors, antiarrhythmic therapy, early rhythm control, stroke prevention

Speakers: V. García, N. Mallofré, D. Calvo, R. del Valle

Session 12 – Chronic Kidney Disease (CKD)

Albuminuria, CKD screening, finerenone and cardiorenal protection

Speakers: C. Amodeo, A. Ribas, E. Sánchez